Skip to main
MEDP

Medpace Holdings (MEDP) Stock Forecast & Price Target

Medpace Holdings (MEDP) Analyst Ratings

Based on 10 analyst ratings
Hold
Strong Buy 0%
Buy 20%
Hold 80%
Sell 0%
Strong Sell 0%

Bulls say

Medpace Holdings is a potential investment opportunity, with strong underlying fundamentals supporting continued bookings ramp and a positive outlook for the company in the future. With a strong presence in the global CRO market, Medpace is well-positioned to capture potential growth in the biopharma industry. However, potential risks associated with the CRO space, such as increased cancellations and challenges in sourcing clinical trial talent, may impact the company's performance in the short term. Overall, the positive outlook is based on the company's strong position in the market, with the potential for growth through increased outsourcing and new clinical trial starts.

Bears say

Medpace Holdings is highly reliant on the biopharma industry and any slowdown or decrease in funding in this sector could severely impact their bookings and revenue growth. Additionally, any delays in government funding or shutdowns could also strain resources and impact Medpace's ability to generate revenue. However, the company's focus on ethical behavior and expertise in key therapeutic areas, as well as positive early-stage clinical trial momentum, could help mitigate some of these potential risks.

Medpace Holdings (MEDP) has been analyzed by 10 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 20% recommend Buy, 80% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medpace Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medpace Holdings (MEDP) Forecast

Analysts have given Medpace Holdings (MEDP) a Hold based on their latest research and market trends.

According to 10 analysts, Medpace Holdings (MEDP) has a Hold consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $560.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $560.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medpace Holdings (MEDP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.